To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease
Ludger Ltd, Culham Science Centre, Abingdon, Oxfordshire, United Kingdom; Division of BioAnalytical Chemistry, VU University Amsterdam, Amsterdam, The Netherlands.
Ludger Ltd, Culham Science Centre, Abingdon, Oxfordshire, United Kingdom.
Translational Gastroenterology Unit, University of Oxford, Oxford, United Kingdom.
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands; Division of Biomolecular Mass Spectrometry and Proteomics, Utrecht University, Utrecht, The Netherlands.
Show others and affiliations
2023 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 17, no 6, p. 919-932Article in journal (Refereed) Published
Abstract [en]

Biomarkers to guide clinical decision-making at diagnosis of inflammatory bowel disease (IBD) are urgently needed. We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients. Forty-seven individual glycan peaks were analysed using ultra-high performance liquid chromatography identifying 105 glycoforms from which 24 derived glycan traits were calculated. Multivariable logistic regression was performed to determine associations of derived glycan traits with disease. Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78). Application to an independent replication cohort of 54 IBD patients yielded a HR of 5.1 (p=1.1×10-5; 95% CI, 2.54-10.1). These data demonstrate the prognostic capacity of serum N-glycan biomarkers and represent a step towards personalized medicine in IBD.

Place, publisher, year, edition, pages
Oxford University Press, 2023. Vol. 17, no 6, p. 919-932
Keywords [en]
Biomarker, Crohn's disease, N-Glycans, Personalised treatment, Prognosis, Ulcerative colitis
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-103595DOI: 10.1093/ecco-jcc/jjad012ISI: 000944979400001PubMedID: 36694402Scopus ID: 2-s2.0-85159095357OAI: oai:DiVA.org:oru-103595DiVA, id: diva2:1731146
Available from: 2023-01-26 Created: 2023-01-26 Last updated: 2023-12-08Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Bergemalm, DanielHalfvarson, Jonas

Search in DiVA

By author/editor
Bergemalm, DanielHalfvarson, Jonas
By organisation
School of Medical Sciences
In the same journal
Journal of Crohn's & Colitis
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 54 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf